Explore 3 Stock Ideas & Industry Insights Download Free Report

small-cap

Leveraged Daily Exposure to Cresco Labs

Dec 22, 2025 | Team Kalkine
Leveraged Daily Exposure to Cresco Labs
Image source: Shutterstock

The Tradr 2X Long CLS Daily ETF seeks to provide twice the daily return of Cresco Labs’ equity performance through the use of derivatives such as total return swaps and other financial instruments, rather than holding the stock directly.

Because leverage is reset daily, performance over periods longer than one trading session can diverge materially from 2x the cumulative return of CLS due to daily compounding effects.

How the Leverage Works

Because the ETF is 2x leveraged on a daily basis:

  • A +1% daily move in CLS is designed to result in an approximately +2% move in the ETF (before fees).
  • A −1% daily move in CLS would generally translate into an approximately −2% move in the ETF.

Over multiple days, returns can vary significantly depending on volatility and the path of price movements, not just the net direction.

Exposure to a High-Beta, Policy-Sensitive Stock

Cresco Labs operates in the U.S. cannabis sector, an industry heavily influenced by:

  • U.S. federal and state-level regulatory developments
  • Cannabis rescheduling discussions
  • SAFE Banking Act progress
  • Earnings results and margin trends
  • Capital market access and investor risk appetite

As a result, CLS often exhibits high daily volatility, which directly impacts the performance—and risk profile—of a 2x leveraged ETF tracking it.

The Tradr 2X Long CLS Daily ETF magnifies both upside and downside moves, making it particularly sensitive to:

  • Earnings announcements
  • Regulatory headlines
  • Broad cannabis sector momentum

Who Should Consider Tradr 2X Long CLS Daily ETF?

This ETF is not designed for buy-and-hold investors. It is best suited for experienced traders who understand leveraged products and monitor positions actively.

Common Use Cases

1.Short-Term Tactical Trading:

Traders with a high-conviction, short-term bullish view on Cresco Labs—perhaps around earnings, regulatory news, or sector momentum—may use the ETF to amplify returns without using margin directly.

2. Event-Driven Positioning:

Investors anticipating near-term catalysts such as earnings surprises, legalization headlines, or sector-wide rallies may deploy the ETF for brief holding periods to express that view.

Key Risks and Strategic Considerations

Before using the Tradr 2X Long CLS Daily ETF, investors should carefully consider:

  • Leverage & Compounding Risk: Returns over periods longer than one day can deviate sharply from 2x CLS performance, especially in volatile or sideways markets.
  • Single-Stock Risk: Exposure is concentrated in one company, increasing idiosyncratic risk versus diversified cannabis ETFs.
  • Sector Volatility: Cannabis equities are among the most volatile segments of the equity market.
  • Daily Reset Risk: The ETF is intended for daily trading, not long-term investment.
  • Higher Expense Ratio & Financing Costs: Leveraged ETFs generally carry higher costs than traditional equity ETFs.

Price Chart Technical Summary

Conclusion

The Tradr 2X Long CLS Daily ETF is a high-risk, high-reward tactical instrument designed to deliver twice the DAILY performance of Cresco Labs. It is best used by active traders seeking short-term exposure to a volatile, catalyst-driven cannabis stock.

While the ETF can generate outsized gains during strong bullish moves in CLS, it also carries meaningful downside risk and is unsuitable for long-term holding. Proper position sizing, disciplined risk management, and a clear understanding of leveraged ETF mechanics are essential when trading this product. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is December 22, 2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings.

Note 4: ‘Kalkine reports are prepared based on the prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.


Disclaimer-

This report (“Report”) has been issued by Kalkine New Zealand Limited (FSP691351) (NZBN:9429047678101) (“Kalkine”). Kalkine is a Financial Advice Provider (“FAP”) and is authorised by a Class 1 Financial Advice Provider Licence issued by Financial Markets Authority (“FMA”) to provide financial advice. Kalkine provides only general financial advice through its research reports following a person becoming a member. The reports contain buy/sell/hold and other recommendations in relation to equity securities, managed funds and other managed investment schemes and other financial advice products. The recommendations and opinions in this Report and on Kalkine website do not take into account any of your investment objectives, financial situation or needs. Before you make a decision about whether to acquire a financial product, you should obtain the Product Disclosure Statement from the product issuer. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. If you act on the advice in the research reports, you may have to pay fees, expenses or other amounts (but not to Kalkine).

The information in this Report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its reports (including this Report), newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not issue, sell or deal in any financial products. The information in this Report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain general recommendations to invest in securities and other financial products. Kalkine is not responsible for, and does not guarantee, the performance of, or returns on, any investments mentioned in this Report.

This Report may contain information on past performance of particular investments. Past performance is not a reliable indicator of future performance. Returns stated do not take into account transaction costs and taxes.

Further information about the complaints and dispute resolution process, as well as information about Kalkine’s duties are available on Kalkine’s website.  Please read our Financial Advice Provider (FAP) disclosure statement and Complaints Handling Guide, which are available on the website.

Copyright 2025 Krish Capital Pty. Ltd. (ABN 61629651510). All Rights Reserved. No part of this Report, or its content, may be reproduced in any form without our prior consent.

Past performance is not a reliable indicator of future performance.